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Abstract
Background: In adults with intellectual disability (ID) and epilepsy there are suggestions that improvements in
management may follow introduction of epilepsy nurse-led care. However, this has not been tested in a definitive
clinical trial and results cannot be generalised from general population studies as epilepsy tends to be more severe
and to involve additional clinical comorbidities in adults with ID. This trial investigates whether nurses with
expertise in epilepsy and ID, working proactively to a clinically defined role, can improve clinical and quality of life
outcomes in the management of epilepsy within this population, compared to treatment as usual. The trial also
aims to establish whether any perceived benefits represent good value for money.
Methods/design: The EpAID clinical trial is a two-arm cluster randomised controlled trial of nurse-led epilepsy
management versus treatment as usual. This trial aims to obtain follow-up data from 320 participants with ID and
drug-resistant epilepsy. Participants are randomly assigned either to a ‘treatment as usual’ control or a ‘defined
epilepsy nurse role’ active arm, according to the cluster site at which they are treated. The active intervention
utilises the recently developed Learning Disability Epilepsy Specialist Nurse Competency Framework for adults with
ID. Participants undergo 4 weeks of baseline data collection, followed by a minimum of 20 weeks intervention
(novel treatment or treatment as usual), followed by 4 weeks of follow-up data collection. The primary outcome is
seizure severity, including associated injuries and the level of distress manifest by the patient in the preceding
4 weeks. Secondary outcomes include cost-utility analysis, carer strain, seizure frequency and side effects.
Descriptive measures include demographic and clinical descriptors of participants and clinical services in which they
receive their epilepsy management. Qualitative study of clinical interactions and semi-structured interviews with
clinicians and participants’ carers are also undertaken.
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Discussion: The EpAID clinical trial is the first cluster randomised controlled trial to test possible benefits of a
nurse-led intervention in adults with epilepsy and ID. This research will have important implications for ID and
epilepsy services. The challenges of undertaking such a trial in this population, and the approaches to meeting
these are discussed.
Trial registration: International Standard Randomised Controlled Trial Number: ISRCTN96895428 version 1.1.
Registered on 26 March 2013.
Keywords: Epilepsy, Intellectual disability, Epilepsy nurse, Treatment, Quality of life, Cost-effectiveness, Clinical trial,
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Background
Introduction – rationale for the trial
In adults with an intellectual disability (ID) and epilepsy
there are suggestions that improvements may follow
introduction of epilepsy nurse-led care. However, this
has not been tested in a definitive clinical trial and re-
sults from previous studies within the general population
cannot necessarily be generalised to adults with ID given
the often relatively greater severity and complexity of
epilepsy and associated morbidities in that group.
Epilepsy and intellectual disability
Nearly one million adults in England have an ID and
epilepsy is the most common medical illness in this
group; affecting around 26 %, with higher rates in those
with more severe ID [1, 2]. Individuals with ID have a
worse outcome than those with epilepsy in the general
population with increased seizure frequency, higher fre-
quency of multiple anti-epileptic drug use and side ef-
fects, higher treatment costs, higher rates of mortality
and greater incidence of behavioural problems [1, 3–5].
Reflecting these observations, it has been reported that
between 2005 and 2009 the most common cause of
avoidable acute hospital admissions for people with ID
was seizures associated with poorly controlled epilepsy
[6]. A survey by the Improving Health and Lives: Learn-
ing Disabilities Observatory (IHAL) reported that the
second most frequent potentially preventable cause of
death in those with ID was epilepsy or convulsions
(13 %) [7]. These observations highlight the need to im-
prove outcomes for people with epilepsy and ID.
Currently in the UK, secondary care of epilepsy and
ID is generally provided by community learning disabil-
ity services, or hospital-based neurological services [8].
It is common for people with ID to be on multiple ther-
apies and they are likely to have tried several anti-
epileptic medications to reduce seizure severity and
frequency [3]. Only around 30 % of this population will
achieve seizure freedom compared to 70 % of the gen-
eral population [1, 4]. Therefore, in most people with
epilepsy and ID, the aim of anti-epileptic medication is
to reduce seizure severity and frequency whilst keeping
associated side effects to a minimum [9]. Achieving this
balance is often difficult in adults with ID due to the epi-
lepsy’s severity and complex associated morbidities. Asso-
ciated morbidities of epilepsy in adults with ID include
difficulty understanding, mobility problems, communica-
tion difficulties, attentional deficits and a range of emo-
tional, cognitive and behavioural problems [1]. Therefore
identifying and differentiating presenting symptoms from
the individuals’ ID, epilepsy and medication side effects
can be problematic. There are often additional challenges
for treating clinicians in communicating effectively with
the individual with ID; putting them at ease and providing
the most effective treatment and management [3], result-
ing in the highest possible overall quality of life for the in-
dividual. Unfortunately, epileptologists may be limited in
being able to provide the necessary clinic time and often
have limited training in ID [3]. Individuals with epilepsy
and ID are also at greater risk of lacking capacity to under-
stand and make decisions regarding their treatment,
meaning that ‘best interest’ decisions may be required,
often involving tripartite discussion between the individ-
ual, their family or paid carer and treating clinician [10].
This suggests that a multidisciplinary, holistic approach,
with judicious use of expert nurses may improve support
and access to healthcare in this group, who are often ex-
cluded from clinical research and overlooked by health
services.
The aim of the trial described in this article is to test
the hypothesis that an epilepsy nurse-led intervention is
able to cost-effectively reduce seizure severity and im-
prove overall quality of life for patients and those that
provide care for them in the community.
Epilepsy Specialist Nurses (EN) role
Epilepsy Nurses (ENs) offer a broad spectrum of services
to patients with epilepsy. They contribute, depending on
their level of training and expertise, to activities that
may include patient assessment, medication manage-
ment and ordering and interpreting investigations [11].
They also provide education, support and counselling to
patients and families, often overlooked by other clini-
cians [12–14]. ENs may also have more time to speak to
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patients [15] and may improve continuity of, and acces-
sibility to care, with the potential to improve communi-
cation between people with epilepsy and their primary
healthcare services [16, 17]. Therefore, it is predicted
that ENs would be ideally placed to champion the un-
predictable, complex and long-term needs of people with
epilepsy [18].
However, a Cochrane review [19] of five trials of epi-
lepsy nurse specialists found no convincing evidence
across the general population that ENs improve overall
outcomes for people with epilepsy. Nevertheless, a
recent open prospective survey, published after the
Cochrane review, of the effects of introducing a paediat-
ric EN, suggested ENs might reduce emergency admis-
sions by as much as 50 % [20]. Thus a state of clinical
equipoise may be considered to exist with respect to the
question of whether it would be effective and cost-
effective to systematically employ ENs to manage epi-
lepsy in adults with ID.
In terms of financial costs, a trial reported by Meads
et al. [21], in patients recruited from a hospital-based
epilepsy service of whom just under 10 % had an ID, noted
that the use of an epilepsy nurse cost less than standard
care, with reduced numbers of outpatient clinic hospital
attendances with doctors and a potential decrease in GP
consultations after 6 months.
The great majority of previous research into the use of
ENs has been in the general population, in studies that
have completely or largely excluded adults with ID.
However, it is known that people with ID have been sub-
ject to a range of health inequalities. Advocacy organisa-
tions and especially Mencap [22] have highlighted
inequalities in healthcare noting that clinicians regularly
fail people with ID - failing to consult with or involve
parents and family members in care and treatment deci-
sions. Despite these observations, a survey of epilepsy
services for a community sample of adults with ID and
epilepsy [23] found that just 34 % of respondents had
seen an EN. This low exposure rate is despite the per-
ception that ENs may enhance the care of people with
ID and epilepsy [24–26].
The Epilepsy and Intellectual Disability (EpAID) Trial - aim
The EpAID Trial aims to address two specific objectives.
The primary objective is to establish whether nurses
with expertise in epilepsy and ID, working to a clinically
defined role outlined by The Learning Disability Epilepsy
Nurse Competency Framework [27], can reduce seizure
severity in adults with ID compared to treatment as
usual.
The secondary objectives are to establish whether any
observed benefits of clinical and quality of life outcomes
justify any additional resource requirements, from the
perspective of Health and Social Services.
Methods/design
Primary objective
To establish whether nurses with expertise in epilepsy
and intellectual disabilities (ID), working to a defined
clinical role, can improve epilepsy-related clinical and
quality of life outcomes in the management of epilepsy
in adults with ID compared to treatment as usual.
Secondary objective
To establish whether any clinical benefits found justify
the provision of additional resources associated with EN
input after consideration of the costs associated with the
intervention from the perspective of Health and Social
Services. Additional secondary outcomes comprise mea-
sures of carer strain and quality of life to examine how
the use of the competency framework, compared to
treatment as usual, impacts on relationships critical in
delivering ongoing care for adults with ID and epilepsy.
Trial design
The study is a cluster randomised trial with two arms; a
‘treatment as usual’ control and a novel ‘defined epilepsy
nurse (EN) role’ trial arm, complying with CONSORT
guidelines for cluster randomised trials [28]. The study
also contains a nested qualitative component. The de-
sign of the trial can be seen in Fig. 1 and the CONSORT
diagram in Fig. 2. A SPIRIT flow diagram describing the
order in which cluster and participant recruitment, clus-
ter randomisation, data collection and intervention pro-
cesses at each research cluster took place is provided in
Fig. 3. A populated SPIRIT checklist is available as an
Additional file 1.
Randomisation of the clusters is undertaken independ-
ently by a Clinical Trials Unit (CTU) supporting the
trial, using block randomisation with fixed block sizes
(in pairs).
The trial is pragmatic in design and formal blinding
around this intervention is not possible. However, steps
have been taken to minimise risks of bias developing, as
described in the appropriate section below.
Methods: participants, interventions, outcomes
What does the trial involve?
The trial compares the effectiveness of the Epilepsy
Nurse (EN) intervention to treatment as usual in 16
community intellectual disability (ID) services. The EN
intervention comprises individually focused active sup-
port and management by an epilepsy nurse working ac-
cording to a specific set of guidelines developed by the
UK Epilepsy Specialist Nurse Association in association
with the UK Royal College of Nursing [27]. The treatment
as usual condition comprises the existing management
approach, which is likely to include some combination of
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input by ID psychiatrists, neurologists, ID nurses and spe-
cialist epilepsy nurses.
Each participant undergoes 4 weeks of baseline data
collection, followed by a minimum of 20 weeks interven-
tion (novel treatment or treatment as usual), followed by
a 4-week period of follow-up data collection. Once the
follow-up data has been obtained for all participants in a
cluster, the study will end for that cluster. Patient re-
cruitment for the first trial site commenced in October
2014.
In addition, a carer and a nurse treating a nested sub-
sample of up to 30 participants from each arm undergo
a qualitative interview, held during the follow-up period.
Six clusters from each arm are randomly selected by the
CTU, in each of which up to five carers and five nurses
are interviewed. These interviewees are not randomly se-
lected but are a convenience sample.
Eligibility criteria
Inclusion criteria:
1. Age 18–65 years.
2. The presence of a developmental intellectual
disability with IQ of 70 or less.
Fig. 1 EpAID trial design. Trial design including the measures to be obtained. CIDT community intellectual disability team, CSI Carer Strain Index,
CSRI Client Service Receipt Inventory, CTU Clinical Trials Unit, ELDQoL Epilepsy and Learning Disabilities Quality of Life scale
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3. A diagnosis of epilepsy with a history of at least one
seizure in the 6 months preceding recruitment into
the study (not considered by those managing the
epilepsy to have been a non-epileptic seizure).
4. A nurse in the Community Intellectual Disability Team
has a current role in delivering some aspects of epilepsy
management at the time of both screening and consent.
Exclusion criteria:
1. The presence of a rapidly progressive physical or
neurological illness.
2. Alcohol or drug dependence.
Intervention
ENs in the intervention arm engage in the following
activities [27]:
– Establish a relationship with patient and carers with
regular collection of clinical information including
seizure frequency, side effects, behavioural
symptoms and effects of seizures on daily life from
patient and carers. ENs also assess the patient on a
regular basis at a frequency determined by clinical
need. This is achieved through home visits,
telephone clinics and visits to the local primary care
or ID team base as appropriate. ENs also help
Fig. 2 CONSORT diagram. A blank CONSORT diagram to record the number of participants enrolled, number allocated to treatment arm, number
lost to follow-up and number analysed
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manage the epilepsy of the participant and
associated complications, as well as providing
epilepsy education to patients and carers. ENs are
the first point of contact for the service user/carer.
The intervention takes place in the community,
delivered face-to-face and by telephone with
participants in their own homes and other community
settings, such as day care facilities, as appropriate.
– Relationships with other clinicians are maintained by
ENs facilitating well-informed assessments by
participants’ primary care health service, local
community ID health team and/or local neurology
service as required.
The ‘treatment as usual’ comparator:
– Participants receive the same management as they
did prior to entering the study. This varies
throughout the country and includes various
combinations of input by ID psychiatrists,
neurologists, ID nurses and epilepsy nurses, often
following locally developed care pathways. The
nature of the ‘treatment as usual’ is described during
the baseline phase of the trial by the use of a
community ID team epilepsy service questionnaire
(Community Intellectual Disability Epilepsy-Service
Availability Questionnaire), and throughout the trial
by use of the EN self-completion activity diary [29].
The ENs are responsible for completing the above
questionnaire and the diary in both arms of the trial.
Training to be received by those delivering treatments
– All nurses receive training for diary completion by
experienced educationalists/epilepsy specialist
nurses. All ENs also have their clinical practice
during the trial monitored by completing the
aforementioned diary on a daily basis. The EN
self-completion diary provides a reliable account of
EN practice at a relatively low cost [30] and has
been used successfully as a data collection method
in a number of EN studies [31–33]. It is anticipated
(from previous studies) that diary entry should take
ENs approximately 15 minutes each day.
Contextual information
– The level of therapist competence at each research
cluster is determined at baseline prior to the start of
the trial according to the criteria described in the
Learning Disability Epilepsy Nurse Competency
Framework [27].
– The resources available locally at each cluster for
providing epilepsy treatment to adults with an ID
are determined at baseline prior to the start of the
trial using a Community Intellectual Disability
Epilepsy-Service Availability Questionnaire.
– The work undertaken by ENs during baseline is
determined during the trial using an EN
self-completion activity diary, which is completed
throughout the period that the trial lasts at each
cluster.
Outcome measures
Primary outcome
– The primary outcome measure is the severity of
seizures following intervention compared to
treatment as usual. Seizure severity is measured
using the Seizure Severity Scale from the Epilepsy
and Learning Disabilities Quality of Life instrument
(ELDQoL-SSS) [34]. The measure is completed at
the end of the 4-week baseline period and again after
24 weeks in the trial. The baseline period refers to
the 4 weeks prior to treatment beginning (whether
Fig. 3 SPIRIT EpAID trial process flow diagram. Flow diagram
describing the order in which cluster and participant recruitment,
cluster randomisation, data collection and intervention processes at
each research cluster took place
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this be continuation of treatment as usual or the
beginning of the nurse-led intervention). The
ELDQoL-SSS is designed for use as a proxy measure;
it is completed by carers and provides a detailed
measure of the physical severity of seizures
experienced in the preceding 4 weeks, including any
associated injuries and the level of distress manifest
by the patient after a seizure.
Secondary outcomes
The secondary outcome measures include an economic
evaluation of the EN intervention. This takes two forms:
a cost-utility analysis based on utility data collected
using the EQ-5D-5 L and a cost-benefit analysis in
which benefit is assessed by contingent valuation of the
service by carers. Differences in resource use are esti-
mated using a modified Client Service Receipt Inventory
[35], collected over the baseline period and again for
4 weeks after 24 weeks of intervention. The majority of
the Client Service Receipt Inventory questionnaires are
collected from paid carers and family carers, with occa-
sional input from participants where a carer is not avail-
able. Time diaries are completed by ENs.
Additional secondary outcome measures:
– A contingent valuation of current practice is
conducted. Maximum willingness-to-pay values
for support from ENs (from carers in both arms)
provides a measure of the strength of preference
across the two service options, collected after at
least 24 weeks in the trial. This instrument is only
employed when the participant’s main carer is a
family member, rather than a paid support
worker.
– The effect of the intervention on carers and
patients, measured using the Carer Strain Index
[36], which is collected in the baseline period and
after at least 24 weeks in the trial.
– The EQ-5D-5L [37], which permits estimation of
changes in health-related quality of life attributable
to the intervention and comparison with the
primary outcome measure (ELDQoL-SSS) in terms
of sensitivity to change.
– Seizure frequency is derived from entries by the
participant’s carer in a seizure diary. Carers are
asked to update this diary on a daily basis, reporting
all seizures experienced by participants during the
baseline and follow-up periods. Seizure frequency
data records the number of types of seizures
alongside the numbers of each type of seizure.
– Occurrence of possible anti-epileptic drug (AED)
adverse effects is assessed using the ELDQoL
questionnaire for the 4-week baseline period and
again for 4 weeks after 24 weeks of intervention.
– Mood and behaviour outcomes are also assessed
using the relevant ELDQoL subscales.
– A series of qualitative semi-structured interviews
of samples of clinicians, family and paid carers
are undertaken during the follow-up period.
These examine how the competency framework,
compared to treatment as usual, impacts on
relationships between the EN and family/paid
carers with respect to their reported perceptions
of patient health and quality of life, the
involvement of patients in treatment decisions
and the active engagement of carers with clinical
epilepsy services.
Descriptive measures
Demographic and clinical descriptors of participants are
collected from participants’ clinical notes at baseline.
The descriptors include the level of ID, nature of accom-
modation (also collected at follow-up), gender, age,
current anti-epilepsy treatment (also collected at follow-
up), and any additional ID syndrome, psychiatric and
neurological diagnoses.
Sample size for quantitative data collection
Data from an earlier study (LD-ROME) examining
the use of the ELDQoL in adults with an ID [8] were
used to estimate the interclass correlation coefficient
(ICC) and individual level standard deviation for the
seizure severity subscale of the ELDQoL outcome
(ELDQoL-SSS). The estimated ICC was near to 0, but
with a wide confidence interval. The estimated stand-
ard deviation of the change in ELDQoL-SSS outcome
from that study was 6.55 [8]. It was chosen to power
the study for the change between the baseline and
follow-up of the ELDQoL-SSS outcome assuming an
ICC of -0.05, which was above the estimated value in
LD-ROME.
Assuming the difference in ELDQoL-SSS at baseline
and after 24 weeks has a standard deviation of 6.55 in
both treatment arms, and an ICC of 0.05, 16 clusters
of 15 patients each would give 86 % power, at a one-
sided 0.025 significance level, to detect a true mean
intervention effect of 3.6. Recruiting 20 patients per
cluster allows for the potential dropout rate of over
10 % (calculated based on the LD-ROME outcome),
without impairing the statistical power of the data
analysis.
Sample size for the qualitative data collection
Sixty pairs of interviews, with carers and clinicians, are
conducted. Participants are determined pragmatically
on the basis of availability, with the aim of including
patients living in a range of social circumstances.
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Recruitment
Participants and recruitment
We aim to recruit 20 participants from each of 16 dif-
ferent community ID services, each of which comprises
a single research cluster, providing a total of 320 par-
ticipants. The recruitment process is summarised in
Fig. 3.
Initially, potential sites, identified by the trial research
team or through local research networks, are contacted
to enquire whether they are willing to participate in the
trial if they meet the criteria of employing one or more
nurses who delivers at least some aspects of epilepsy
management to patients with ID and epilepsy and if they
have at least 50 current patients with ID and epilepsy.
Following recruitment of a site, members of the direct
clinical care team supported, where appropriate permis-
sions have been gained, by nurses from the local clinical
research network, screen all potential participants. An
anonymised list of eligible potential participants is sent
to the clinical trials unit (CTU) supporting the trial, who
provide the research team with a sequence in which to
contact them. The first 34 potential participants are con-
tacted in the first instance. If any potential recruit does
not wish to participate then the next person in the se-
quence is approached. Participant recruitment is com-
pleted before site randomisation.
Methods: assignment of interventions
Group allocation
Sequence generation
Randomisation of the clusters is undertaken independ-
ently by the CTU using block randomisation with fixed
block sizes. A minimum of two sites are randomised at a
time to preserve allocation concealment. Site details are
submitted to the CTU after potential participants within
the centre have been identified and the randomisation
outcome is confirmed to relevant members of the study
team. Cluster randomisation to treatment arm takes
place close to the start of the intervention phase to min-
imise the risk of clusters withdrawing between random-
isation and the start of the trial.
Concealment mechanism
The nature of the active intervention, being a change in
working protocols for the nurse, is such that the study
cannot be fully blind. However, measures are taken to
minimise the risk of bias being introduced. These are
listed below:
– There is random selection of participants into the
trial at each cluster and random allocation of each
cluster to treatment arm.
– Individual cluster sites are not informed of the
intervention they are to deliver until the month
prior to the intervention phase and only after
participant recruitment at that site is completed.
– In order to minimise expectations of the
participants, their carers and families and the
clinical staff at each cluster, they are not informed
that there are two arms to the trial – ‘active’ and
‘treatment as usual’. Nor are they informed which
arm of the study they are in. They are told instead
about the range of interventions included in the trial
and that their treatment may or may not change.
– It is expected that the ongoing management
variability that is often a feature of management of
drug-resistant epilepsy will blur perceived variations
in management associated with the two arms of the
study. Nevertheless, it is possible that some participants
and their carers/paid support workers may notice
differences in the management they receive during
the trial.
– The people involved in the research informed of
which arm a cluster has been randomised to are
staff at the CTU undertaking the randomisation, the
academic nurse providing training to the ENs
delivering the trial interventions, and the Chair of
the Trial Data Monitoring and Ethics Committee
(DMEC) if requested. All other members of the
research team remain blind to which arm a cluster
has been randomised into.
– Data collection by researchers is via telephone or at
participants’ homes/day placements. The nurses
delivering the treatment interventions are not
present at these assessments.
– The primary and the majority of the secondary
outcome measures take the form of structured
questionnaires and respondents are asked to
consider their responses to these questions before
reporting them to the researchers collecting the
data.
Methods: data collection, management, analysis
Data collection methods
Obtaining patient consent, together with collection of
patient baseline and follow-up data is undertaken by
Research Assistants employed by the University of
Cambridge and in some cases by Research Network
Nurses at the trial cluster sites. The majority of the data
collection is undertaken over the telephone by Research
Assistants. Research Assistants mostly talk to carers of
participants, due to the nature of the questions being
asked. This also bypasses any issues which may arise for
participants whose level of intellectual disability is too
severe for them to provide details for the data collection.
The use of telephone interviews allows a more convenient
and low-cost method of data collection than face-to-face
interviews. Participants/carers are sent the questionnaires
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in advance of the telephone call and then their answers
are noted by the research assistant during the prearranged
talk. Qualitative interviews are conducted and audio-
recorded over the telephone for later transcription. A
willingness-to-pay health economic questionnaire is also
collected over the phone during the follow-up phase.
Data management
The trial employs an electronic case report form (eCRF)
created using the InferMed Macro database system. Data
is managed via this system. The eCRF is created in col-
laboration with the trial statistician and the chief investi-
gator and maintained by the CTU. It is hosted on a
dedicated secure server within the CTU’s host academic
institution. The system is regulatory compliant (good
clinical practice (GCP), 21CRF11, EC Clinical Trial Dir-
ective) with a full audit trail, data discrepancy function-
ality, database lock functionality, and supports real-time
data cleaning and reporting.
The trial manager is responsible for requesting user-
names and passwords via the CTU for permitted local
study personnel. There are different permission levels
given to the system by virtue of individual usernames.
Only those authorised by the trial manager are able to
use the system. Paper CRFs are available as a back-up.
Quality assurance
The study incorporates a range of data management
quality assurance functions. The eCRF system contains a
range of validations that alert sites to inconsistencies in
the data being entered, which is monitored by the trial
manager. The trial manager provides relevant staff train-
ing, ongoing study support and monitors study data as it
accumulates, checking source data for transcription er-
rors. Any necessary alterations to entered data are date
and time stamped within the eCRF.
The monitoring and data management plan are up-
dated as the trial progresses, detailing the quality control
and quality assurance checks to be undertaken.
All members of the research team who have direct
contact with participants have received good clinical
practice training and informed consent training. Further,
questionnaires used in the study are validated and refer-
ences can be found in the ‘measures’ section.
Statistical methods
Data analysis
Data is entered electronically into an online database on
a secure server. No patient is identifiable from the infor-
mation recorded about them. Paper copies of data collec-
tion tools are kept in a locked filing system with restricted
access at the University of Cambridge.
Clinical outcome analyses
The difference in treatment outcome between the com-
petency framework arm and the treatment as usual arm
is calculated as the difference between the baseline and
follow-up ELDQoL-SSS measurement. A linear mixed-
effects model is used with a random effect for cluster to
account for the trial being cluster randomised. Baseline
patient covariates to be included as fixed-effects are
ELDQoL-SSS, age, level of intellectual disability (mild,
moderate, severe or profound), mean number of seizures
per month averaged over the 4 weeks preceding entry to
the trial, and living circumstances (independent; with
family; in group home). Cluster level covariates included
as fixed-effects are the deprivation index of the cluster
area, seniority level of the nurse (‘novice’, ‘competent’ or
‘expert’) to investigate possible therapist effects, and
overall caseload of the nurse (number of patients).
Whether a nurse is a nurse-prescriber is also recorded.
The seniority criteria are such that a nurse-prescriber is
rated as ‘expert’. However, preliminary data indicate that
fewer than 10 % of nurses are prescribers and it is unlikely
that prescriber status will be independently considered as
a covariate. A Wald test for effect of intervention is used
as the primary analysis.
Missing data on the ELDQoL-SSS are dealt with using
a missing at random assumption. Where >3 % of data
are missing, multiple imputation is used for the primary
analysis. Five imputations are used unless the percentage
missingness is greater than this. In this case the number
of imputations is equal to the percentage missingness.
Multiple imputation is also performed on missing covar-
iate and outcome data for all secondary clinical analyses
in a similar way to the primary analysis.
Secondary outcomes are analysed using a suitable
mixed-effects model (linear mixed-effects model for
continuous outcomes, and a Poisson generalised linear
mixed-effects model for count data) or accounting for
the clustering using robust Huber-White standard er-
rors. Secondary clinical endpoints include the change in
Carer Strain Index, the number of seizures and the other
subscales of the ELDQoL measurement (side effects,
mood and behaviour). The covariates used for the ana-
lysis of the secondary outcomes are the same as those
included in the primary outcome measure.
Economic analyses
A cost-utility analysis is used to evaluate effectiveness.
The cost-utility analysis will allow comparison of cost-
effectiveness against commonly accepted thresholds of
acceptability in terms of the cost per quality-adjusted
life-year (QALY) gained [38]. However, given the poten-
tial for a lack of sensitivity of the EQ-5D-5 L to benefits
of the intervention for carers and for participants, we
will also undertake a cost-benefit analysis. The time
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horizon of each evaluation is 6 months and the primary
perspective is Health and Social Services.
A sensitivity analysis will consider a broader societal
perspective. Cost differences across the two arms of the
trial are estimated from questionnaires assessing provision
of health and social care at baseline and after 6 months,
and from time diaries completed by ENs. QALY gains
are estimated at 0.5* health-related quality of life (QoL)
at 6 months after controlling for QoL at baseline,
ELDQoL-SSS, age, level of ID, mean number of seizures
per month (calculated as above), and living circum-
stances (as above). Willingness-to-pay data are col-
lected as open-ended responses with the use of prompt
cards showing a range of values. Bootstrapping is used
to estimate uncertainty in mean cost and outcomes,
and to facilitate construction of cost-effectiveness ac-
ceptability curves for the cost-utility analysis. Boot-
strapping refers to a statistical technique to estimate
uncertainty around a parameter without assuming a
parametric distribution for the population distribution
of that parameter.
Qualitative analysis
The semi-structured interviews are analysed using a sys-
tematic process of indexing - thematic framework devel-
opment; charting; mapping and interpretation. We will
examine how the competency framework, compared to
treatment as usual, impacts on relationships between the
EN and family/paid carers with respect to (i) reported
perceptions of patient health and quality of life, (ii) the
involvement of patients in treatment decisions and (iii)
the active engagement of carers with clinical epilepsy
services.
Safety procedure
It is not expected that there are any major negative ef-
fects on participants resulting from participating in this
trial. No clinically indicated treatment is withheld in
either arm of the trial. However, serious adverse events
which might be expected include an increase in seizure
frequency or severity, occurrence of uncontrolled sei-
zures requiring paramedic support or hospital admission
and emergence of anti-epileptic drug-related adverse
effects.
The Principal Investigator (PI) at each cluster site is
responsible for recording all serious adverse events and
reporting them to the Chief Investigator (CI), via the
Trial Coordinator, on trial serious adverse events forms.
The Chief Investigator will then report all serious ad-
verse events to the sponsor. Any serious adverse events
classified as ‘related’ and ‘unexpected’ will be reported to
the main Research Ethics Committee (REC) within
15 days of becoming aware.
Ethics, dissemination and patient and public
involvement
Research ethics approval
This protocol has received ethical approval from the
National Research Ethics Service (London Queen Square
Committee) and, for Scotland, the Scotland A Research
Ethics Committee. Amendments are reported to all
study sites and the trial oversight committees. In order
to enable inclusion of adults lacking capacity to decide
whether to participate in research, appropriate approvals
are sought from family or care providers, in line with ss.
30-34 of the Mental Capacity Act (England and Wales
2005) [39] or section 51 of the Adults with Incapacity
Act (Scotland 2000) [40]. Those for whom consent/
assent is not obtained will not participate in the study
and will continue to receive their standard management.
Consent/assent
All participants’ family carers or paid support workers
and, where possible the participants themselves, are in-
formed about the potential risks and benefits of the
study. Study information is presented in terms of a writ-
ten information sheet and also as an accessible ‘easy-
read’ information sheet. Informed written consent is ob-
tained for all participants. In England and Wales either
the participant provides consent or if capacity to consent
is absent, written assent is provided by a consultee. In
Scotland informed consent is given either by the partici-
pant or, if they lack capacity, their nearest relative, wel-
fare attorney or welfare guardian.
Confidentiality
The Chief Investigator acts as custodian for the trial
data. The following guidelines are strictly adhered to:
– Patient data are anonymised on the eCRF and paper
CRF.
– All anonymised data are stored on a password-
protected computer
Patient and public involvement
All research studies funded by the UK NIHR are re-
quired to demonstrate good-quality patient and public
involvement (PPI). The patient group involved in the
EpAID study present difficulties in terms of representa-
tion as individuals with severe intellectual disabilities are
more likely to have epilepsy. They are thus more likely
to make up a large proportion of the participant group
recruited for this trial. The Trial Advisory Group (TAG)
for this study has attempted to overcome these chal-
lenges and ensure the views of those with severe ID are
represented, along with their families and paid carers
and the general public, through the experience and ex-
pertise of its members.
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TAG members include the mother of a young woman
with a severe ID and complex epilepsy and a home
manager with experience of care for people with ID and
epilepsy. The advisory group also consists of a represen-
tative from the charity Epilepsy Action who is able to
consult through volunteer and adviser contacts and find
family carers or members of the public to give views
about specific questions as they arise. Joining the TAG
are a Learning Disability Nurse with experience in the
management of epilepsy, the trial CI, Co-ordinator,
Research Assistants and other members of the research
team as required.
The group address issues relevant to recruitment,
retention and dissemination of findings. They advise on
how to interact with participants and carers and help to
make sure that important outcomes are not overlooked.
Meetings happen at intervals of approximately 3 months
but remain flexible to incorporate each stage of the re-
search process. Advice gained through the TAG is acted
upon and reported by the research team throughout the
trial.
Discussion
The EpAID Trial investigates whether an EN-led epi-
lepsy management programme is effective and repre-
sents good value for money for people with an ID and
epilepsy compared to current management (treatment as
usual).
The trial methodology brings both strengths and
weaknesses. Cluster randomisation protects against
contamination [41]. Within each cluster the EN(s) will
manage participants using just one approach. There are
16 individual cluster sites across England, Scotland and
Wales, increasing the external validity of the trial. The
inclusion of multiple different healthcare delivery organi-
sations (NHS Trusts) within the trial increases the diver-
sity of the population being studied, increasing the
generalisability of the study.
However, the complex intervention to be trialled can-
not be delivered and assessed in a double-blind manner
[42]. Although participants will not be told which arm of
the trial they are in, it is possible that they and their
caregivers could notice a difference in their manage-
ment. Moreover, the Hawthorne effect has the potential
to influence this study, as clinicians in both arms may
try to improve the management they provide for patients
involved in the study [42], possibly overshadowing effects
of the intervention.
Fidelity of delivery of the intervention is assessed by
examination of activity diaries completed by the ENs.
ENs could have large numbers of diaries to fill, so there
is a chance that information could be omitted or forgot-
ten. Previous studies have found this not to be the case
[31, 32]. However, these studies did not have the volume
of participants included in the EpAID Trial and it is pos-
sible that this could be detrimental to the accuracy and
consistency of diary entries.
The following steps to minimise attrition are included
as part of the trial design; (i) participation in the trial
makes very few active demands on the participants, (ii)
participants are eligible because they have ongoing sei-
zures, meaning that they are likely to be agreeable to
remaining in the trial, (iii) participation in the trial does
not preclude receipt of any other clinically indicated
treatment, (iv) the research team follows a flexible
participant-led approach to gathering baseline and
follow-up data – with contacts being at times and loca-
tions suggested by participants and respondents, and
with, as far as possible, contacts being either face-to-
face, by telephone or by post as preferred by respon-
dents. There are, however, issues that may arise when
using telephone contact to complete questionnaires.
Questionnaire interviews conducted over the phone may
be more readily misunderstood than face-to-face inter-
views, even if the participant has a copy of the relevant
questionnaire in front of them (which may not always be
possible). On the other hand, telephone calls may be
more convenient for participants and carers as they can
be scheduled around the needs of the participant, redu-
cing the risks of failure or delay in obtaining baseline or
follow-up measures.
There is a growing importance in evaluating the cost-
effectiveness of clinical interventions alongside their
efficacy [43]. This allows decision-makers to prioritise
investment in a manner which reflects efficiency as well
as equity concerns [44]. This importance is recognised
by the EpAID Trial, which will involve two complemen-
tary economic evaluations: a cost-utility analysis captur-
ing gains in participant QoL and allowing comparison
against accepted thresholds (£20,000 per QALY), and a
cost-benefit analysis that has the scope to capture a
broader range of benefits to participants and their
carers. These evaluations will provide the necessary data
for commissioners of health services to assess whether
to implement an EN service given the constraints of a
limited budget.
The EpAID Trial investigates treatments for epilepsy
in adults who also have an intellectual disability. As
noted in the introduction, there is a clear need for re-
search to improve epilepsy management in this group.
However, undertaking a clinical trial in this population
brings several challenges that need to be overcome.
These include recruiting individuals who lack capacity to
provide informed consent to participate and identifying
appropriate consultees for these individuals. Some indi-
viduals have been in residential care for many years,
occasionally with limited or no contact with family
members. To overcome these challenges we work closely
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with the community teams who deliver care to this pa-
tient group, and through them, aim to constructively in-
volve carers, particularly family carers. The importance
of this approach is illustrated in a previous qualitative
study of parents of adults with ID and epilepsy, which
observed that, in their role as gatekeepers for access by
health services to their grown-up children, the extent to
which parents facilitated their offspring’s participation in
therapeutic activities depended on the parents’ views, as
opposed to clinicians’ views, of those activities [10].
Further issues may be related to participants being in
group homes. Informed consent can be more difficult to
gauge when the participant is reliant on others. The par-
ticipant’s choices may be limited – they may be used to
saying ‘yes’ or ‘no’ to every option [45], which clouds
their ability to make a judgement related to informed
consent. Furthermore, the researcher may be seen as an
authority figure, leading to acquiescence – the person in
authority makes a decision and the participant simply
goes along with it [46].
The EpAID research could have important implica-
tions for ID and epilepsy services. If the intervention is
found to be effective and cost-effective it will improve
epilepsy outcomes for service users with ID, as they will
receive more effective treatments. If on the other hand
the intervention is found to be no more effective than
current treatments, this knowledge will enable service
commissioners and managers to deploy clinicians to
other roles.
Trial status
The study began in October 2013, recruitment commenced
in October 2014.
Trial protocol
Date 30 July 2015, Version 1.5.
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